| Sep 10 |
Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive
|
| Sep 10 |
Terns Pharmaceuticals reports positive data from Phase I trial of obesity treatment
|
| Sep 9 |
Terns Pharmaceuticals launches $125M public offering
|
| Sep 9 |
Terns Announces Proposed Public Offering
|
| Sep 9 |
Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill
|
| Sep 9 |
Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month
|
| Sep 9 |
Top 2 Health Care Stocks That May Collapse This Quarter
|
| Sep 9 |
Terns stock jumps as weight loss drug succeeds in early trial
|
| Sep 9 |
Early study data puts Terns among obesity drug contenders
|
| Sep 9 |
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
|
